Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized clinical tria...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of women's health (Larchmont, N.Y. 2002) N.Y. 2002), 2022-05, Vol.31 (5), p.698-705
Hauptverfasser: Stewart, Elizabeth A, Archer, David F, Owens, Charlotte D, Barnhart, Kurt T, Bradley, Linda D, Feinberg, Eve C, Gillispie-Bell, Veronica, Imudia, Anthony N, Liu, Ran, Kim, Jin Hee, Al-Hendy, Ayman
Format: Artikel
Sprache:eng
Schlagworte:
Female
Gonadotropin-Releasing Hormone - therapeutic use
Humans
Hydrocarbons, Fluorinated
Leiomyoma - complications
Leiomyoma - drug therapy
Menorrhagia - drug therapy
Original
Pyrimidines
Uterine Neoplasms - complications
Uterine Neoplasms - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized clinical trials (Elaris UF-1 and UF-2). Responders were defined as women who met both primary end point bleeding criteria (
ISSN:1540-9996
1931-843X
1931-843X
DOI:10.1089/jwh.2021.0152